Acrivon Therapeutics, Inc. ACRV
1.57 USD 0.00 (+0.00%)
At closeNov 12, 2026, 7:46 AM EST
1.60 +0.03 +1.91%
Pre-market · Nov 12, 7:46 AM ET
1.55 Day range 1.65
1.27 52-week range 3.56
- YTD
- -34.85%
- 1 year
- -24.15%
News
seekingalpha.com Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
benzinga.com Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
globenewswire.com Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease
benzinga.com Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
benzinga.com Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft modelsPrioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…- benzinga.com Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of…
benzinga.com Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly…
benzinga.com Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24 Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei…- benzinga.com Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of…
benzinga.com Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
benzinga.com Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses…- benzinga.com Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates…
benzinga.com Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8 Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.
benzinga.com Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, while confirming cash runway into 2027.
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - benzinga.com Market-Moving News for January 8th ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial…
- benzinga.com Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical Data From ACR-2316 Phase 1 Trial, Nominates Next AP3-Enabled Preclinical Development Candidate ACR-6840 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Acrivon Therapeutics to Release New Cancer Drug Data on Jan. 8 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026 Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.
- benzinga.com Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
- benzinga.com Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.20% to 38,972.32 while the NASDAQ rose…
benzinga.com Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 127 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.